Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free QNRX Stock Alerts

Quoin Pharmaceuticals (QNRX) Financials

Quoin Pharmaceuticals logo
$5.09 -0.96 (-15.87%)
Closing price 04:00 PM Eastern
Extended Trading
$5.00 -0.09 (-1.75%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Quoin Pharmaceuticals

Annual Income Statements for Quoin Pharmaceuticals

This table shows Quoin Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -40 -59 -13 -185 -1.56 -2.10 -21 -9.45 -8.69 -8.96 -16
Consolidated Net Income / (Loss)		 -40 -59 -13 -185 -1.56 -2.10 -21 -9.38 -8.69 -8.96 -16
Net Income / (Loss) Continuing Operations		 -40 -59 -13 -185 -1.56 -2.10 -21 -9.38 -8.69 -8.96 -16
Total Pre-Tax Income 		-40 -59 -13 -185 -1.56 -2.10 -21 -9.38 -8.69 -8.96 -16
Total Operating Income		 -39 -61 0.00 -219 -1.56 -1.67 -6.06 -9.26 -9.38 -9.53 -16
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 39 62 0.00 219 1.56 1.67 6.06 9.26 9.38 9.53 16
Selling, General & Admin Expense		 16 31 -45 59 1.51 1.43 4.50 6.58 6.07 5.93 6.49
Research & Development Expense		 23 32 -40 51 0.05 0.24 1.56 2.67 3.31 3.60 9.80
Total Other Income / (Expense), net		 -0.29 3.49 -13 34 0.00 -0.43 -15 -0.12 0.69 0.57 0.49
Interest & Investment Income		 0.02 2.54 0.35 34 - - 0.00 0.10 0.69 0.56 0.48
Other Income / (Expense), net		 0.00 1.08 - - 0.00 -0.38 -14 0.08 -0.00 0.01 0.00
Basic Earnings per Share		 $0.14 - $0.87 $0.16 ($0.52) ($0.70) ($67.96) ($46.81) ($9.64) ($68.02) ($14.80)
Weighted Average Basic Shares Outstanding		 74.48M 91.13M 111.97M 129.43M 1.20B 1.20B 315.80K 201.83K 900.92K 131.76K 1.07M
Diluted Earnings per Share		 $0.14 - $0.87 $0.16 ($0.52) ($0.70) ($67.96) ($46.81) ($9.64) ($68.02) ($14.80)
Weighted Average Diluted Shares Outstanding		 74.48M 91.13M 111.97M 129.43M 1.20B 1.20B 315.80K 201.83K 900.92K 131.76K 1.07M
Weighted Average Basic & Diluted Shares Outstanding		 74.48M 91.13M 111.97M 129.43M 212.64M 368.08M 3.35B 59.24B 3.69M 41.17M 64.93M

Quarterly Income Statements for Quoin Pharmaceuticals

This table shows Quoin Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.93 -2.05 -2.33 -1.97 -2.35 -2.31 -3.81 -3.70 -3.95 -4.35 -5.00
Consolidated Net Income / (Loss)		 -1.93 -2.05 -2.33 -1.97 -2.35 -2.31 -3.81 -3.70 -3.95 -4.35 -5.00
Net Income / (Loss) Continuing Operations		 -1.93 -2.05 -2.33 -1.97 -2.35 -2.31 -3.81 -3.70 -3.95 -4.35 -5.00
Total Pre-Tax Income 		-1.93 -2.05 -2.33 -1.97 -2.35 -2.31 -3.81 -3.70 -3.95 -4.35 -5.00
Total Operating Income		 -2.13 -2.22 -2.46 -2.14 -2.53 -2.41 -3.96 -3.79 -4.02 -4.52 -5.13
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 2.13 2.22 2.46 2.14 2.53 2.41 3.96 3.79 4.02 4.52 5.13
Selling, General & Admin Expense		 1.37 1.39 1.57 1.55 1.45 1.35 1.58 1.74 1.74 1.42 1.70
Research & Development Expense		 0.76 0.83 0.89 0.59 1.08 1.05 2.37 2.05 2.28 3.10 3.43
Total Other Income / (Expense), net		 0.20 0.17 0.13 0.16 0.18 0.09 0.14 0.10 0.07 0.17 0.13
Interest & Investment Income		 0.20 0.16 0.14 0.17 0.15 0.11 0.14 0.10 0.06 0.17 0.15
Other Income / (Expense), net		 0.00 0.01 -0.01 -0.00 0.03 -0.02 0.00 -0.01 0.01 0.00 -0.01
Basic Earnings per Share		 ($1.95) ($2.28) ($38.73) ($13.68) ($16.29) ($17.54) ($6.50) ($6.28) ($6.71) ($4.07) ($1.77)
Weighted Average Basic Shares Outstanding		 987.22K 900.92K 60.09K 144.28K 144.28K 131.76K 586.33K 588.17K 588.17K 1.07M 2.83M
Diluted Earnings per Share		 ($1.95) ($2.28) ($38.73) ($13.68) ($16.29) ($17.54) ($6.50) ($6.28) ($6.71) ($4.07) ($1.77)
Weighted Average Diluted Shares Outstanding		 987.22K 900.92K 60.09K 144.28K 144.28K 131.76K 586.33K 588.17K 588.17K 1.07M 2.83M
Weighted Average Basic & Diluted Shares Outstanding		 - 3.69M 7.96M 7.96M 10.10M 41.17M 21.17M 21.17M 30.20M 64.93M 72.30M

Annual Cash Flow Statements for Quoin Pharmaceuticals

This table details how cash moves in and out of Quoin Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 6.99 -131 26 -28 -52 0.32 7.16 -4.62 -0.46 1.22 0.19
Net Cash From Operating Activities		 -30 -61 -62 -78 -52 -1.34 -5.72 -8.48 -7.86 -7.86 -14
Net Cash From Continuing Operating Activities		 -30 -61 -62 -78 -52 -1.34 -5.72 -8.48 -7.86 -7.86 -14
Net Income / (Loss) Continuing Operations		 -40 -59 -98 -75 -58 -2.10 -21 -9.38 -8.69 -8.96 -16
Consolidated Net Income / (Loss)		 -40 -59 -98 -75 -58 -2.10 -21 -9.38 -8.69 -8.96 -16
Amortization Expense		 - - - - - 0.10 0.10 0.10 0.10 0.10 0.10
Non-Cash Adjustments To Reconcile Net Income		 5.40 0.52 21 -4.86 3.58 0.38 15 0.89 0.62 1.01 0.93
Changes in Operating Assets and Liabilities, net		 3.93 -4.03 14 0.16 1.33 0.27 0.63 -0.09 0.10 -0.00 1.23
Net Cash From Investing Activities		 12 -70 35 50 -0.39 -0.13 -0.63 -10 2.19 -1.89 -4.28
Net Cash From Continuing Investing Activities		 -1.00 -70 -0.92 50 -0.39 -0.13 -0.63 -10 2.19 -1.89 -4.28
Purchase of Investments		 - - - - - - 0.00 -9.90 -18 -17 -12
Sale and/or Maturity of Investments		 - 11 - 52 0.00 - - 0.00 20 15 7.99
Net Cash From Financing Activities		 25 0.00 55 0.00 0.00 1.79 14 14 5.22 11 18
Net Cash From Continuing Financing Activities		 25 0.00 55 0.00 0.00 1.79 14 14 5.22 11 18
Repayment of Debt		 - - - - - -0.05 -0.30 -0.91 -0.60 -0.60 -0.60
Issuance of Common Equity		 25 - 50 - - - - - - 12 19
Effect of Exchange Rate Changes		 - - - - - - - - - 0.00 -0.00

Quarterly Cash Flow Statements for Quoin Pharmaceuticals

This table details how cash moves in and out of Quoin Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.60 -0.76 -0.57 1.01 0.27 0.51 0.20 -2.15 0.16 1.99 -0.69
Net Cash From Operating Activities		 -1.32 -3.22 -1.43 -2.01 -2.18 -2.24 -2.59 -3.69 -2.23 -5.04 -4.87
Net Cash From Continuing Operating Activities		 -1.32 -3.22 -1.43 -2.01 -2.18 -2.24 -2.59 -3.69 -2.23 -5.04 -4.87
Net Income / (Loss) Continuing Operations		 -1.93 -2.05 -2.33 -1.97 -2.35 -2.31 -3.81 -3.70 -3.95 -4.35 -5.00
Consolidated Net Income / (Loss)		 -1.93 -2.05 -2.33 -1.97 -2.35 -2.31 -3.81 -3.70 -3.95 -4.35 -5.00
Amortization Expense		 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Non-Cash Adjustments To Reconcile Net Income		 0.13 0.20 0.21 0.29 0.25 0.26 0.29 0.25 0.18 0.21 0.33
Changes in Operating Assets and Liabilities, net		 0.45 -1.40 0.66 -0.35 -0.10 -0.21 0.90 -0.26 1.51 -0.92 -0.23
Net Cash From Investing Activities		 0.00 2.64 -4.47 3.16 2.60 -3.18 2.77 1.68 2.54 -11 4.12
Net Cash From Continuing Investing Activities		 0.00 2.64 -4.47 3.16 2.60 -3.18 2.77 1.68 2.54 -11 4.12
Purchase of Investments		 -4.60 - -9.65 - -1.61 -6.00 0.00 - - -12 -0.98
Sale and/or Maturity of Investments		 4.60 2.64 5.18 3.16 4.21 2.82 2.77 1.68 2.54 1.00 5.10
Net Cash From Financing Activities		 -0.28 -0.18 5.33 -0.14 -0.15 5.92 0.02 -0.15 -0.15 18 0.06
Net Cash From Continuing Financing Activities		 -0.28 -0.18 5.33 -0.14 -0.15 5.92 0.02 -0.15 -0.15 18 0.06
Repayment of Debt		 -0.28 -0.15 -0.15 -0.15 -0.15 -0.15 -0.15 -0.15 -0.15 -0.15 -0.15
Other Financing Activities, net		 - -0.03 5.48 0.01 0.00 - 0.17 - - - 0.21
Effect of Exchange Rate Changes		 - - - - - - 0.00 - - - 0.00

Annual Balance Sheets for Quoin Pharmaceuticals

This table presents Quoin Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 130 105 77 74 1.38 9.36 14 12 16 20
Total Current Assets		 125 99 70 64 0.47 8.20 13 11 15 20
Cash & Equivalents		 24 48 67 63 0.32 7.48 2.86 2.40 3.62 3.82
Short-Term Investments		 95 49 - - - 0.00 9.99 8.29 10 15
Prepaid Expenses		 - - - - 0.00 0.72 0.52 0.59 0.87 1.26
Plant, Property, & Equipment, net		 5.28 4.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.60 5.79 4.45 0.91 1.16 1.09 0.88 0.78 0.38
Intangible Assets		 - - - - 0.91 0.81 0.70 0.58 0.48 0.38
Total Liabilities & Shareholders' Equity		 130 105 77 74 1.38 9.36 14 12 16 20
Total Liabilities		 21 40 25 22 7.99 8.70 7.05 6.51 6.50 7.27
Total Current Liabilities		 13 14 18 13 0.96 4.58 3.53 3.58 4.18 5.55
Accounts Payable		 13 14 18 11 0.00 1.77 0.61 0.53 0.91 1.26
Accrued Expenses		 - - - - 0.96 1.69 1.18 1.31 1.53 2.54
Other Current Liabilities		 - - - 1.37 - 0.37 0.60 0.60 0.60 0.60
Other Current Nonoperating Liabilities		 - - - - - 0.74 1.15 1.15 1.15 1.15
Total Noncurrent Liabilities		 7.45 26 6.81 9.85 7.02 4.12 3.52 2.92 2.32 1.72
Other Noncurrent Operating Liabilities		 7.45 26 - - 7.02 - 3.52 2.92 2.32 1.72
Commitments & Contingencies		 0.00 0.00 - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 110 65 52 51 -6.61 0.66 7.41 5.66 9.20 13
Total Preferred & Common Equity		 110 65 52 51 -6.61 0.66 7.41 5.66 9.20 13
Total Common Equity		 110 65 52 51 -6.61 0.66 7.41 5.66 9.20 13
Common Stock		 259 287 - - 0.00 32 48 52 64 84
Retained Earnings		 -137 -222 -315 -349 -6.61 -28 -38 -46 -55 -71
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - - 0.00 -0.00

Quarterly Balance Sheets for Quoin Pharmaceuticals

This table presents Quoin Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 15 16 14 11 13 8.91 6.42 16
Total Current Assets		 14 15 13 10 12 8.48 6.02 15
Cash & Equivalents		 3.16 1.83 2.85 3.12 3.82 1.67 1.83 3.12
Short-Term Investments		 11 13 9.73 7.19 7.73 6.12 3.58 11
Prepaid Expenses		 0.16 0.57 0.65 0.19 0.94 0.69 0.60 1.29
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.93 0.86 0.83 0.89 0.46 0.43 0.41 0.36
Intangible Assets		 0.63 0.56 0.53 0.51 0.46 0.43 0.41 0.36
Total Liabilities & Shareholders' Equity		 15 16 14 11 13 8.91 6.42 16
Total Liabilities		 7.65 7.00 6.58 5.95 7.03 6.36 7.64 6.92
Total Current Liabilities		 4.58 4.22 3.95 3.47 4.86 4.34 5.76 5.35
Accounts Payable		 0.24 0.36 0.82 0.22 0.64 0.87 1.86 1.78
Accrued Expenses		 2.59 2.12 1.39 1.50 2.47 1.72 2.16 1.82
Other Current Liabilities		 0.60 0.60 0.60 0.60 0.60 0.60 0.60 0.60
Other Current Nonoperating Liabilities		 1.15 1.15 1.15 1.15 1.15 1.15 1.15 1.15
Total Noncurrent Liabilities		 3.07 2.77 2.62 2.47 2.17 2.02 1.87 1.57
Other Noncurrent Operating Liabilities		 3.07 2.77 2.62 2.47 2.17 2.02 1.87 1.57
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 7.41 9.13 7.48 5.44 5.93 2.55 -1.21 8.77
Total Preferred & Common Equity		 7.41 9.13 7.48 5.44 5.93 2.55 -1.21 8.77
Total Common Equity		 7.41 9.13 7.48 5.44 5.93 2.55 -1.21 8.77
Common Stock		 54 58 58 58 65 65 65 85
Retained Earnings		 -44 -49 -51 -53 -59 -63 -67 -76
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - -0.00

Annual Metrics And Ratios for Quoin Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Quoin Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 120,140,659.00 130,414,799.00 224,087,799.00 390,949,079.00 3,354,650,799.00 3,354,650,799.00 1,974,440.00 10,099,440.00 30,203,156.00
DEI Adjusted Shares Outstanding		 0.00 0.00 95.00 104.00 889.00 1,551.00 53,248.00 53,248.00 56,413.00 288,555.00 30,203,156.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -138,351.55 -1,778,858.46 -1,755.23 -1,350.98 -403.07 -177.41 -153.98 -31.06 -0.52
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -50.51% 102.19% -16,965.25% 99.88% -616.63% -928.29% 54.61% -2.23% -1.55% -71.82%
EBIT Growth		 0.00% -52.87% 100.00% 0.00% 99.29% -31.27% -881.14% 54.33% -2.20% -1.49% -71.06%
NOPAT Growth		 0.00% -55.60% 100.00% 0.00% 99.29% -7.02% -263.04% -52.70% -1.30% -1.60% -70.97%
Net Income Growth		 0.00% -48.38% 77.68% -1,307.56% 99.16% -34.28% -924.29% 56.29% 7.41% -3.18% -76.34%
EPS Growth		 0.00% 0.00% 0.00% -1,307.56% 99.16% -34.28% -924.29% 56.29% 79.41% -3.18% 78.24%
Operating Cash Flow Growth		 0.00% -102.98% -0.89% -27.20% 33.78% 97.42% -327.31% -48.26% 7.27% 0.09% -72.34%
Free Cash Flow Firm Growth		 0.00% 0.00% 166.43% -902.97% 97.66% 82.41% -1,171.67% 55.10% -68.70% 1.90% -55.22%
Invested Capital Growth		 0.00% 0.00% -219.93% 70.12% 31.83% -6.85% 71.75% -119.62% 9.67% 4.60% -20.86%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.31% -14.90%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.28% -14.80%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.01% -14.92%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.00% -14.80%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.00% 36.78%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 11.16% -26.05%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -30.26%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.35% 18.28%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.74% 97.78% 0.00% 84.38% 100.00% 102.30% 106.79% 102.20% 92.60% 94.13% 97.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -53.77% -15.03% -314.78% -3.02% -9.38% 721.40% -232.68% -132.92% -120.56% -141.59%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -53.77% -15.03% -314.78% -3.02% -9.38% 721.40% -232.68% -132.92% -120.56% -141.59%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -53.77% -20.11% -354.52% -3.04% 31.71% -3,266.60% -126.66% -153.36% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -28 -43 0.00 -153 -1.09 -1.17 -4.24 -6.48 -6.56 -6.67 -11
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -26.75% -12.13% -39.69% -0.78% -3.19% -1,171.72% -40.51% -19.96% -20.42% -28.85%
Return On Investment Capital (ROIC_SIMPLE)		 - - 0.00% - - - - - -115.91% -72.46% -86.92%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -39 -60 0.00 -219 -1.56 -2.05 -20 -9.18 -9.38 -9.52 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -39 -59 1.29 -218 -0.27 -1.94 -20 -9.08 -9.28 -9.42 -16
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.23 0.04 0.02 0.01 0.33
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.02 0.01 0.34
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.13 0.19 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.13 0.19 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.09 -1.24 -1.35 -1.15 -1.30 0.49 -1.78 -1.63 -1.51 -1.37
Leverage Ratio		 0.00 1.19 1.35 1.55 1.46 1.68 -1.80 2.95 2.04 1.88 1.62
Compound Leverage Factor		 0.00 1.16 0.00 1.31 1.46 1.72 -1.93 3.02 1.89 1.77 1.57
Debt to Total Capital		 0.00% 0.00% 0.00% 11.54% 16.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 11.54% 16.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 88.46% 83.89% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 -0.03 -36.29 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.28 198.52 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.03 -36.29 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.04 -9.01 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.40 49.31 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.04 -9.01 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -14.25 -5.85 -12.02 -10.81 -4.88 -7.09 -6.09 -6.30
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 9.30 6.97 3.80 5.11 0.48 1.79 3.79 3.15 3.57 3.61
Quick Ratio		 0.00 9.30 6.97 3.80 5.11 0.34 1.64 3.64 2.99 3.36 3.38
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -33 22 -176 -4.12 -0.72 -9.22 -4.14 -6.98 -6.85 -11
Operating Cash Flow to CapEx		 -3,023.53% -1,255.49% -6,680.45% -3,187.20% -12,206.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -259.75 1.62 -2,345.20 0.00 -15.41 -6.75 -13.88 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -97.59 -481.27 -4.57 -1,045.40 0.00 -28.47 -4.19 -28.45 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -100.82 -519.61 -4.63 -1,078.20 0.00 -28.47 -4.19 -28.45 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -9.95 -32 -9.52 -6.49 -6.93 -1.96 -4.30 -3.88 -3.71 -4.48
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -9.95 -22 22 3.03 -0.44 4.97 -2.34 0.42 0.18 -0.77
Enterprise Value (EV)		 0.00 0.00 0.00 -61 -54 0.08 -7.33 -13 -11 -14 -14
Market Capitalization		 0.00 0.00 0.00 0.21 0.05 0.40 0.15 0.32 0.10 0.07 4.36
Book Value per Share		 $0.00 $1.20 $0.58 $0.43 $0.39 ($0.03) $0.00 $0.00 $2.87 $0.91 $0.43
Tangible Book Value per Share		 $0.00 $1.20 $0.58 $0.43 $0.39 ($0.03) $0.00 $0.00 $2.57 $0.86 $0.42
Total Capital		 0.00 110 65 59 61 -6.61 0.66 7.41 5.66 9.20 13
Total Debt		 0.00 0.00 0.00 6.81 9.85 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 6.81 9.85 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -119 -97 -61 -54 -0.32 -7.48 -13 -11 -14 -19
Capital Expenditures (CapEx)		 1.00 4.86 0.92 2.46 0.43 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -8.32 -12 -17 -12 -0.82 -3.86 -3.01 -2.99 -3.31 -4.28
Debt-free Net Working Capital (DFNWC)		 0.00 111 85 51 52 -0.50 3.62 9.84 7.70 11 14
Net Working Capital (NWC)		 0.00 111 85 51 52 -0.50 3.62 9.84 7.70 11 14
Net Nonoperating Expense (NNE)		 12 16 13 32 0.47 0.93 17 2.90 2.12 2.29 4.40
Net Nonoperating Obligations (NNO)		 0.00 -119 -97 -62 -58 -0.32 -2.62 -12 -9.55 -13 -18
Total Depreciation and Amortization (D&A)		 0.28 1.35 1.29 1.72 1.29 0.10 0.10 0.10 0.10 0.10 0.10
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $2,628.00 $0.00 $165.60 $108.00 ($18.00) ($561.60) ($9.64) ($66.85) ($14.80)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 3.34K 3.62K 31.12K 54.30K 880.50K 16.82K 900.92K 133.96K 1.07M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $2,628.00 $0.00 $165.60 $108.00 ($18.00) ($561.60) ($9.64) ($66.85) ($14.80)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 3.34K 3.62K 31.12K 54.30K 880.50K 16.82K 900.92K 133.96K 1.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $2,628.00 $0.00 $165.60 $108.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 3.11K 3.60K 29.53K 51.12K 1.86M 411.42M 3.69M 1.18M 64.93M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -43 0.00 -153 -1.09 -1.17 -4.24 -6.48 -6.56 -6.67 -11
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -127.81 -474.67 0.00 -2,924.70 0.00 -43.56 -14.72 -30.79 0.00 0.00 0.00
NOPAT to Interest Expense		 -89.47 -338.21 0.00 -2,047.29 0.00 -24.86 -3.11 -21.74 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -131.04 -513.00 -0.07 -2,957.50 0.00 -43.56 -14.72 -30.79 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -92.69 -376.54 -0.07 -2,080.09 0.00 -24.86 -3.11 -21.74 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Quoin Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Quoin Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 59,234,012,016.00 1,974,440.00 3,685,970.00 7,959,940.00 7,959,940.00 10,099,440.00 41,171,660.00 21,173,996.00 21,173,996.00 30,203,156.00 64,930,556.00
DEI Adjusted Shares Outstanding		 1,692,400,343.00 56,413.00 105,313.00 227,427.00 227,427.00 288,555.00 1,176,333.00 21,173,996.00 21,173,996.00 30,203,156.00 64,930,556.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -36.34 -22.10 -8.68 -10.33 -8.01 -3.24 -0.17 -0.19 -0.14 -0.08
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 0.00% 10.60% 6.80% -17.84% -9.75% -61.16% -78.51% -61.27% -87.64% -30.20%
EBIT Growth		 0.00% 0.00% 10.54% 6.77% -17.58% -9.61% -60.54% -77.59% -60.66% -86.73% -30.01%
NOPAT Growth		 0.00% 0.00% 11.43% 5.44% -18.95% -8.45% -60.97% -77.49% -59.02% -87.96% -29.67%
Net Income Growth		 0.00% 0.00% 10.59% 6.31% -21.97% -12.75% -63.80% -87.23% -68.02% -88.14% -31.10%
EPS Growth		 0.00% 0.00% 10.59% 6.31% -21.97% -12.75% -63.80% 54.09% 58.81% 76.80% 72.77%
Operating Cash Flow Growth		 0.00% 0.00% 17.87% -27.62% -64.91% 30.62% -80.86% -83.66% -2.12% -125.13% -87.69%
Free Cash Flow Firm Growth		 0.00% 0.00% -181.74% -177.39% 0.00% 0.00% 19.85% 15.58% -153.96% -28.41% -45.84%
Invested Capital Growth		 0.00% 0.00% 27.28% 27.22% 0.00% 4.60% -1.41% -3.72% -47.38% -20.86% 7.96%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 7.56% -4.08% -11.78% 13.34% -16.88% 3.06% -64.14% 4.01% -5.60% -12.79% -13.89%
EBIT Q/Q Growth		 7.47% -4.02% -11.61% 13.21% -16.69% 3.03% -63.47% 3.99% -5.56% -12.71% -13.81%
NOPAT Q/Q Growth		 5.97% -4.35% -10.85% 13.06% -18.29% 4.86% -64.54% 4.14% -5.98% -12.45% -13.51%
Net Income Q/Q Growth		 8.56% -6.39% -13.53% 15.18% -19.04% 1.64% -64.94% 3.05% -6.82% -10.14% -14.93%
EPS Q/Q Growth		 8.45% -16.92% -13.53% 15.18% -19.04% 1.64% -64.94% 3.38% -6.85% 39.34% 56.51%
Operating Cash Flow Q/Q Growth		 15.97% -143.93% 55.50% -39.93% -8.58% -2.63% -15.99% -42.10% 39.63% -126.25% 3.30%
Free Cash Flow Firm Q/Q Growth		 -100.00% 0.00% 0.00% 12.03% 165.60% -195.53% -45.40% 7.35% 58.07% -127.33% -65.13%
Invested Capital Q/Q Growth		 100.00% 0.00% -13.74% 10.69% 5.75% 0.35% -20.90% 8.66% -33.92% 18.28% 7.93%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 90.75% 92.82% 94.42% 92.27% 94.14% 95.48% 96.34% 97.28% 98.45% 96.20% 97.15%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -132.92% -83.94% -111.17% -159.90% -120.56% -138.82% -242.67% -651.40% -141.59% -231.18%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -132.92% -83.94% -111.17% -159.90% -120.56% -138.82% -242.67% -651.40% -141.59% -231.18%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -92.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.49 -1.55 -1.72 -1.50 -1.77 -1.68 -2.77 -2.66 -2.81 -3.16 -3.59
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -5.21% -3.97% -3.94% -12.67% -5.59% -8.70% -11.52% -16.89% -7.76% -12.07%
Return On Investment Capital (ROIC_SIMPLE)		 - -27.41% -18.86% -20.00% -32.52% -18.29% -46.75% -104.07% 231.67% -24.12% -40.94%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.12 -2.21 -2.46 -2.14 -2.50 -2.42 -3.96 -3.80 -4.01 -4.52 -5.14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.10 -2.18 -2.44 -2.11 -2.47 -2.40 -3.93 -3.77 -3.99 -4.50 -5.12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.02 0.01 0.01 0.01 0.01 0.02 0.77 0.00 0.33 0.49
Price to Tangible Book Value (P/TBV)		 0.00 0.02 0.01 0.01 0.01 0.01 0.02 0.92 0.00 0.34 0.51
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.69 -1.52 -1.63 -1.68 -1.51 -1.59 -1.80 -3.18 -1.37 -1.59
Leverage Ratio		 0.00 2.04 1.73 1.96 2.09 1.88 1.93 2.29 4.21 1.62 1.95
Compound Leverage Factor		 0.00 1.89 1.63 1.80 1.97 1.79 1.86 2.23 4.15 1.56 1.89
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -5.15 -3.89 -4.74 -6.48 -4.60 -6.67 -10.51 -16.41 -4.39 -6.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 3.15 3.61 3.35 3.02 3.57 2.57 1.95 1.04 3.61 2.87
Quick Ratio		 0.00 2.99 3.48 3.18 2.97 3.36 2.38 1.80 0.94 3.38 2.63
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 -3.38 -2.97 1.95 -1.86 -2.71 -2.51 -1.05 -2.39 -3.95
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -3.88 -4.42 -3.95 -3.72 -3.71 -4.48 -4.09 -5.48 -4.48 -4.12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 1.66 1.48 -3.72 0.18 -0.06 -0.15 -1.76 -0.77 0.36
Enterprise Value (EV)		 0.00 -11 -15 -13 -10 -14 -11 -5.84 -3.89 -14 -9.76
Market Capitalization		 2,458 0.10 0.07 0.05 0.04 0.07 0.09 1.95 1.52 4.36 4.29
Book Value per Share		 $0.00 $2.87 $1.24 $0.94 $0.68 $0.91 $0.14 $0.12 ($0.06) $0.43 $0.14
Tangible Book Value per Share		 $0.00 $2.57 $1.16 $0.87 $0.62 $0.86 $0.13 $0.10 ($0.08) $0.42 $0.13
Total Capital		 0.00 5.66 9.13 7.48 5.44 9.20 5.93 2.55 -1.21 13 8.77
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -11 -15 -13 -10 -14 -12 -7.79 -5.41 -19 -14
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -2.99 -3.65 -3.30 -3.28 -3.31 -3.91 -3.65 -5.16 -4.28 -4.05
Debt-free Net Working Capital (DFNWC)		 0.00 7.70 11 9.27 7.02 11 7.64 4.14 0.25 14 9.99
Net Working Capital (NWC)		 0.00 7.70 11 9.27 7.02 11 7.64 4.14 0.25 14 9.99
Net Nonoperating Expense (NNE)		 0.44 0.50 0.61 0.48 0.58 0.63 1.04 1.04 1.13 1.18 1.41
Net Nonoperating Obligations (NNO)		 0.00 -9.55 -14 -11 -9.16 -13 -10 -6.64 -4.27 -18 -13
Total Depreciation and Amortization (D&A)		 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.28) ($38.85) ($13.65) ($16.45) ($613.90) ($6.50) ($6.28) ($6.71) ($4.07) ($1.77)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 900.92K 60.09K 144.28K 144.28K 3.77K 586.33K 588.17K 588.17K 1.07M 2.83M
Adjusted Diluted Earnings per Share		 $0.00 ($2.28) ($38.85) ($13.65) ($16.45) ($613.90) ($6.50) ($6.28) ($6.71) ($4.07) ($1.77)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 900.92K 60.09K 144.28K 144.28K 3.77K 586.33K 588.17K 588.17K 1.07M 2.83M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.28) $0.00 $0.00 $0.00 ($613.90) $0.00 $0.00 $0.00 ($4.07) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 3.69M 227.43K 227.43K 288.56K 1.18M 21.17M 21.17M 30.20M 64.93M 72.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.49 -1.55 -1.72 -1.50 -1.77 -1.68 -2.77 -2.66 -2.81 -3.16 -3.59
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Quoin Pharmaceuticals remains a pre-revenue biotechnology company with substantial ongoing research and development spending. The latest statements show some improvement in liquidity compared with late 2025, but the company continues to generate significant operating losses and consume cash.

  • Liquidity improved substantially in Q1 2026. Cash and short-term investments totaled approximately $14.0 million at March 31, 2026, up from about $5.4 million at September 30, 2025. Total current assets increased to $15.3 million from $6.0 million over that period.
  • QNRX reported positive shareholders’ equity. Total equity was approximately $8.8 million in Q1 2026, compared with negative equity of $1.2 million in Q3 2025. This improvement primarily reflects financing activity rather than operating profitability.
  • Current liquidity currently exceeds current obligations. Q1 2026 current assets were approximately 2.9 times current liabilities, providing a stronger short-term balance-sheet position than in Q3 2025, when current liabilities exceeded current assets.
  • Debt repayments have continued. The company recorded $150,000 of debt repayment in each of the reported quarters, and total liabilities declined to $6.9 million in Q1 2026 from $7.6 million in Q3 2025.
  • Investment income provides a modest offset to operating losses. Interest and investment income was $146,775 in Q1 2026, although this covered only a small portion of the company’s $5.1 million in operating expenses.
  • Investment transactions are driving much of the cash-flow volatility. QNRX generated $4.1 million from investing activities in Q1 2026, mainly from selling or receiving maturities on investments. This is not recurring operating cash flow and should not be viewed as revenue or sustainable profitability.
  • The company has reported no revenue in the supplied quarters. Total revenue and gross profit were both zero in every reported income statement from Q2 2024 through Q1 2026, leaving QNRX dependent on financing and existing investments to fund development.
  • Operating losses have widened. Q1 2026 net loss was approximately $5.0 million, compared with $4.3 million in Q4 2025 and $3.8 million in Q1 2025. Operating expenses rose to $5.1 million from $4.5 million in the preceding quarter.
  • Research and development spending is accelerating. R&D expense increased to $3.4 million in Q1 2026 from $3.1 million in Q4 2025 and $2.4 million in Q1 2025. This spending may support future pipeline development, but it is also increasing near-term cash requirements.
  • Cash burn remains substantial and external funding will likely remain important. QNRX used $4.9 million in operating cash during Q1 2026. Its $14.0 million of cash and short-term investments equates to roughly three quarters of operating cash burn at the latest quarterly rate, before considering changes in spending, investment income or future financing.

Overall, QNRX’s balance sheet is stronger than it was in mid-to-late 2025, largely because of financing activity and investment sales. However, the company has not yet produced revenue, remains deeply unprofitable and continues to consume cash. Investors should closely monitor clinical progress, future financing terms, operating expenses and potential dilution.

08/14/26 11:16 PM ETAI Generated. May Contain Errors.

Quoin Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Quoin Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Quoin Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$15.80 million in 2025, falling from -$39.69 million in 2015. The previous period was -$8.96 million in 2024. See Quoin Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Quoin Pharmaceuticals' total operating income in 2025 was -$16.29 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $16.29 million

Over the last 10 years, Quoin Pharmaceuticals' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Quoin Pharmaceuticals' total liabilities were at $7.27 million at the end of 2025, a 11.8% increase from 2024, and a 65.1% decrease since 2016.

In the past 9 years, Quoin Pharmaceuticals' cash and equivalents has ranged from $323.83 thousand in 2020 to $66.75 million in 2018, and is currently $3.82 million as of their latest financial filing in 2025.

Over the last 10 years, Quoin Pharmaceuticals' book value per share changed from 0.00 in 2015 to 0.43 in 2025, a change of 43.4%.


Related Companies

Financial statements for NASDAQ:QNRX last updated on 8/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The Shocking Discovery Investigators Found Hidden Inside America's Port Cranes
U.S. investigators found unexplained cellular modems inside cranes made by a Chinese state-owned company that ...
Altimetry | Sponsoredtc pixel
How a rare metal shortage sent gains up 2512 percent
In 2010, a rare earth metal called dysprosium surged 2,512 percent in two and a half years after China cut exp...
Awesomely | Sponsoredtc pixel